Is Thyrocare Tech. overvalued or undervalued?

Jul 01 2025 08:02 AM IST
share
Share Via
As of June 30, 2025, Thyrocare Tech. is considered overvalued with a valuation grade of expensive, a PE ratio of 57.19, and a current price of 989.05, despite a strong annual return of 55.96%.
As of 30 June 2025, the valuation grade for Thyrocare Tech. has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 57.19, an EV to EBITDA of 26.66, and a Price to Book Value of 9.59.

In comparison to its peers, Max Healthcare has a significantly higher PE ratio of 109.43, while Apollo Hospitals, which is rated attractive, has a PE ratio of 71.96. Despite a strong return of 55.96% over the past year compared to the Sensex's 5.79%, the elevated valuation ratios suggest that Thyrocare Tech. is not a compelling investment at its current price of 989.05.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News